JPH0491029A - Galenical drug blended chewable tablet - Google Patents

Galenical drug blended chewable tablet

Info

Publication number
JPH0491029A
JPH0491029A JP2205109A JP20510990A JPH0491029A JP H0491029 A JPH0491029 A JP H0491029A JP 2205109 A JP2205109 A JP 2205109A JP 20510990 A JP20510990 A JP 20510990A JP H0491029 A JPH0491029 A JP H0491029A
Authority
JP
Japan
Prior art keywords
tablet
chewable tablet
galenical
oil
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2205109A
Other languages
Japanese (ja)
Other versions
JPH0739350B2 (en
Inventor
Yosuke Miyamoto
宮本 陽右
Munehiro Negishi
宗広 根岸
Masao Seiki
清木 雅雄
Shigeru Ueki
茂 上木
Hiroyuki Aida
会田 浩幸
Takeshi Higuchi
樋口 武志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Priority to JP2205109A priority Critical patent/JPH0739350B2/en
Publication of JPH0491029A publication Critical patent/JPH0491029A/en
Publication of JPH0739350B2 publication Critical patent/JPH0739350B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To stimulate the feeling of taste and smell in addition to direct action on gastric mucosa and enhance the secretion of saliva and gastric juice and the motility of alimentary canal by preparing a chewable tablet obtained by blending one or more kinds of galenical ordinary stomachics therein. CONSTITUTION:A medicine obtained by combining and blending one or more kinds of galenical drugs such as Cinnamini Cortex, Zingiberis Rhizoma, Atratylodis Lanceae Rhizoma, Menthae Herba, Curcumae Rhizoma, Swertiae Herba or Piscrasmae Lignum is blended with a sugar alcohol, cane sugar, lactose, etc., which are used as additives and the blend is prepared in the form of a chewable tablet. The chewable tablet disintegrates quickly in mouth by chewing and can be administered without water. Hardness thereof is preferably 5-15kg/cm<2>. The tablet is useful as a stomachic because the tablet enhances motility of stomach immediately after administration and the enhancing action id further long-active.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は、生薬を配合するチュγプル錠に関する。さら
に詳しくは、生薬を配合した健胃薬の有用性を高めたチ
ュアブル錠に関する。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to Chugamma tablets containing crude drugs. More specifically, the present invention relates to chewable tablets that enhance the usefulness of stomach medicines containing herbal medicines.

[従来の技術] 健胃薬は、苦味や芳香により味覚・嗅覚を刺激して反射
的に唾液・胃液の分l・を促し、胃などの消化器の運動
を亢進させる薬物で、生薬が用いられると定義され(薬
学大事典、1982年、175項)、臨床上、食欲不振
、消化液分泌不良等の治療の目的で一般的な内服製剤(
錠剤、顆粒剤、散剤、液剤等)として用いられている。
[Conventional technology] Stomach medicines are drugs that stimulate the sense of taste and smell with bitterness and aroma, stimulate the reflex production of saliva and gastric juice, and increase the movement of digestive organs such as the stomach, and are made from crude drugs. (Pharmaceutical Encyclopedia, 1982, Section 175), and is a commonly used oral preparation (Clinically) for the treatment of anorexia, poor secretion of digestive juices, etc.
It is used as tablets, granules, powders, liquids, etc.).

健Wl薬として用いる生薬には、芳香性、辛味性または
苦味性成分を含有するものが多く、これらの成分は、胃
粘膜を直接刺激してガストリンの放出を促し、胃液の分
泌を促進する以外に、味覚や嗅覚を刺激し延髄を介して
反則的に唾液や胃液の分泌、さらに消化管の運動を促進
させることが知られている(内科、金子ら、L且、65
(1987)、薬局、瀬用ら、エエ、39(1984)
)。
Many of the herbal medicines used as health medicines contain aromatic, pungent, or bitter ingredients, and these ingredients have no effect other than directly stimulating the gastric mucosa, promoting the release of gastrin, and promoting the secretion of gastric juice. It is known that it stimulates the sense of taste and smell, promotes the secretion of saliva and gastric juice via the medulla oblongata, and promotes the movement of the gastrointestinal tract (Internal Medicine, Kaneko et al., L., 65).
(1987), Pharmacy, Seyo et al., AE, 39 (1984)
).

方、チニアブル錠は口中で咀噌又は溶解させて服用する
錠剤で、鎮量刑やビタミン剤の一部に適用されているに
過ぎない。
On the other hand, tinable tablets are tablets that are taken by chewing or dissolving in the mouth, and are only used in some sedatives and vitamin preparations.

[発明が解決しようとするnH] 従来の一般的な健胃薬の内服製剤では服用後、薬剤が速
やかに胃内に到達するため、胃粘膜への直接作用が主と
なり、味覚・嗅覚への刺激作用がほとんど期待できなか
った。
[NHH to be solved by the invention] In the conventional oral preparations of general gastric medicines, the medicine reaches the stomach quickly after taking it, so it mainly acts directly on the gastric mucosa, stimulating the sense of taste and smell. I could hardly expect any effect.

このため健胃薬が本来有する薬理作用を十分がつ持続的
に発揮し、従来の健冑薬の有用性を高める製剤の開発が
望まれていた。
Therefore, it has been desired to develop a preparation that can fully and sustainably exert the inherent pharmacological action of stomach medicines and enhance the usefulness of conventional stomach medicines.

[課題を解決するための手段] 本発明者等は、胃粘膜への直接作用はもとより、味覚・
嗅覚を刺激して唾液・胃液の分泌と消化管の運動を高め
る作用を併せ持つ健胃薬の剤型を種々検討した結果、生
薬を配合する薬剤をチコアブル錠とすることにより、前
記課題を解決することを見い出し、本発明を完成した。
[Means for Solving the Problems] The present inventors have discovered that in addition to having a direct effect on the gastric mucosa,
As a result of examining various formulations of stomach medicine that has the effect of stimulating the sense of smell and increasing the secretion of saliva and gastric juices as well as the movement of the gastrointestinal tract, the above-mentioned problem was solved by creating a medicine containing crude drugs in the form of Chicoable tablets. They discovered this and completed the present invention.

即ち、本発明は生薬を配合する健阿薬のチュアブル錠に
関し、強力、速効性かつ持続的に健胃作用を有する健胃
チニアブルを提供する。
That is, the present invention relates to a chewable tablet containing a herbal medicine, and provides a chewable tablet that has strong, fast-acting, and long-lasting effects on the stomach.

本発明において生薬とは通常の健胃薬を1種又はそれ以
上配合するものである。通常の健胃薬としては、たとえ
ばウイキ冒つ、ケイヒ、/lIウキロウ、ソウジコッ、
チ膠ウジ、ハツカ、サンシ1つ、チンピ、オウゴン、ビ
ヤクジュツ等の芳香性成分を含有する生薬類、ウィキ藁
つ油、ケイヒ油、ン謬つ生茸つ油、ン替つズク油、チ1
ウノ油、トウヒ油、ハツカ油、レモン油等の精油類、ウ
コン、トウガラシ等の辛味性成分を含有する生薬類、オ
ウレン、ゲンチアナ、コウボク、センブーハ ニガキ、
ホップ等の苦味性成分を含有する生薬類等々が挙げられ
る。
In the present invention, herbal medicines are those containing one or more conventional stomachic medicines. Typical stomach medicines include, for example, Uiki Hokutsu, Keihi, /lI Ukirou, Soujikok,
Herbal medicines containing aromatic ingredients such as 100% maggot, 100% chimpanzee, 1x chimpi, scutellariae, and 100% sardine, 1x straw oil, 100% cinnamon oil, 1x raw mushroom oil, 1x oil, 1x chili
Essential oils such as uno oil, spruce oil, pepper oil, and lemon oil, herbal medicines containing pungent ingredients such as turmeric and chili pepper, orientale, gentian, koubok, sembuha bittern,
Examples include crude drugs containing bitter components such as hops.

これらの生薬は、一種もしくは二種以上を組み合わせて
配合することができる。また、これらの生薬に他の医薬
活性成分を配合して用いても良い。
These crude drugs may be used alone or in combination of two or more. Further, these crude drugs may be used in combination with other pharmaceutically active ingredients.

本発明のチニアブル錠には、特に支障のない限り、一般
の錠剤の製造に用いられる添加剤を適宜使用することが
できる。例えば、乳糖、糖アルコール、還元麦芽糖水飴
、コーンスターチ、アビセル、粉糖、ステアリン酸マグ
ネンウム等の賦形剤、テンフン、/11糖、ゼラチン、
アラビアゴム末、メチルセルロース、カルボ亭ジメチル
セルロースナトリウム、ヒドロキノプロピルメチルセル
ロース、ポリビニルピロリド7等の結合剤、カルボ手ジ
メチルセルロースカル/ウム、L−ヒドロキノプロピル
セルロース等の崩壊剤、その他項味剤、吸着剤、防腐剤
、湿潤剤、崩壊延長剤等を適宜添加できる。
In the tinable tablets of the present invention, additives used in the production of general tablets can be used as appropriate, unless there is any particular problem. For example, lactose, sugar alcohol, reduced maltose starch syrup, corn starch, Avicel, powdered sugar, excipients such as magnenium stearate, tenfun, /11 sugar, gelatin,
Binder such as gum arabic powder, methylcellulose, sodium dimethylcellulose, hydroquinopropylmethylcellulose, polyvinylpyrrolid 7, disintegrants such as carboxydimethylcellulose, L-hydroquinopropylcellulose, other flavoring agents, Adsorbents, preservatives, wetting agents, disintegration prolonging agents, etc. can be added as appropriate.

チュアブル錠は、噛むことにより口中で速やかに崩壊し
、かつ水無しで服用できる剤型である必要性から、添加
剤として、マンニトール、ソルビトール、キンリトール
等の糖アルコール、白糖、乳糖、粉末還元麦芽糖水飴等
を好ましく配合する。
Chewable tablets need to be in a dosage form that quickly disintegrates in the mouth when chewed and can be taken without water, so additives include sugar alcohols such as mannitol, sorbitol, and quinlitol, white sugar, lactose, and powdered reduced maltose starch syrup. etc. are preferably blended.

また、必要に応じ人工甘味料等により、味覚の面で服用
し易いように製剤設計がなされる。
In addition, if necessary, the formulation is designed to be easy to take in terms of taste by adding artificial sweeteners or the like.

これらの添加剤に対し、生薬は通常1〜30%、好まし
くは1−10%の比率で配合される。
The crude drug is usually added at a ratio of 1 to 30%, preferably 1 to 10%, to these additives.

本発明のチュアブル錠の%2遣方法について、特に制限
はなく通常の錠剤の製造方法である直接打錠法及び間接
打錠法等により製造することができる。
There are no particular restrictions on the method of producing the chewable tablets of the present invention, and the chewable tablets can be produced by a direct tableting method, an indirect tableting method, etc., which are ordinary tablet manufacturing methods.

本発明のチュアブル錠の硬度は、噛み砕き易い硬さが必
要であることから5〜15kg/cm2が好ましい。
The hardness of the chewable tablet of the present invention is preferably 5 to 15 kg/cm 2 because it needs to be hard enough to be easily chewed.

[作用] 次に本発明の有用性をラットの胃運動に対する効果によ
り説明する。
[Effect] Next, the usefulness of the present invention will be explained by the effect on gastric motility in rats.

艮1亙ヱ 雄性SD系ラット(約200g)を−週間予備飼育して
使用した。24時時間量後、エーテル麻酔下にて開腹し
て前背部を小切開し、カテーテルを接続したゴム製バル
ーン、並びに胃内投与力テ−f ルヲ挿入して結紮固定
した。さらに、バルンに水1mlを注入し、バルーンカ
テーテルは低圧トランスジューサー(LPU−0,1−
350゜TM+)に接続した。
Male SD rats (approximately 200 g) were pre-fed for one week and used. After 24 hours of administration, the abdomen was opened under ether anesthesia, a small incision was made in the anterior and dorsal region, and a rubber balloon connected to a catheter and an intragastric injection force table were inserted and ligated and fixed. Furthermore, 1 ml of water was injected into the balloon, and the balloon catheter was connected to a low pressure transducer (LPU-0,1-
350°TM+).

ラットが充分覚醒したのち自発運動による胃内圧の変化
をアンプ(TYPE1236:三栄v)により増幅し、
レコーダー(RECTT−HORIZ−8に: 三栄!
8+)により記録した。薬物は自発運動の発生が安定し
たのち投与し、胃内圧の変化は40分間記録した。
After the rat was fully awake, changes in intragastric pressure due to spontaneous movement were amplified using an amplifier (TYPE 1236: Sanei v).
Recorder (to RECTT-HORIZ-8: Sanei!
8+). The drug was administered after the generation of spontaneous movements stabilized, and changes in intragastric pressure were recorded for 40 minutes.

薬物は下記処方の成分を0.4mlの精製水に墾濁し被
験液とした。
The drug was prepared by suspending the ingredients of the following formulation in 0.4 ml of purified water to prepare a test solution.

効果の判定は、チコアブル錠服用を想定した口腔内及び
胃内の同時投与と、対照例として従来の内服製剤を想定
した胃内のみの投与にょる冑収縮頻度の比較により行っ
た。
The effectiveness was determined by comparing the frequency of cap contractions between simultaneous administration in the oral cavity and stomach, assuming the administration of Chicoable tablets, and administration only in the stomach, assuming a conventional oral formulation as a control example.

処方l ウイキ璽つ油 2.5mg ケイヒ油 3.0mg チ卿つジ油 1.0mg シ望つ半画つ乾燥エキス  5.0mgホップ乾燥エキ
ス     5.0mgカンゾウエキス末    23
.0mg処方2 ウイキ冒つ油       2.5mgケイヒ油   
       3.Omgチョウノ油        
1.0mgmワンキョウ乾燥エキス  5.0mgソウ
ジュツ乾燥エキス  12.0mgカンゾウエキス末 
   23.0mg投与方法は、チーアブル錠を想定し
て被験液の0.2〜Iを口腔内、さらに0.2〜Iを胃
内へ同時に投与した。対照として、従来の内服製剤を想
定し被験液0.4mlを胃内へ直接投与した。
Prescription 2.5mg Wiki linseed oil 3.0mg Cinnamon oil 1.0mg Citrus chinensis oil 1.0mg Shibatsu Hanbatsu dried extract 5.0mg Hops dried extract 5.0mg Licorice extract powder 23
.. 0mg Prescription 2 Wiki-Kotsu Oil 2.5mg Cinnamon Oil
3. Omg butterfly oil
1.0mgm Licorice Dried Extract 5.0mg Soju Dry Extract 12.0mg Licorice Extract Powder
The 23.0 mg administration method was to simultaneously administer 0.2 to 1 of the test liquid into the oral cavity and further 0.2 to 1 into the stomach assuming a chewable tablet. As a control, 0.4 ml of the test solution was administered directly into the stomach assuming a conventional oral preparation.

胃運動の解析は、TAKEUCH1等の方法(Take
uchiら、 Dig、 Dis、 Se4. 、31
.1114−1122、(19g+1))に従い10分
間当りの収縮頻度を測定した。すなわち、20CmH2
0以上を示す収縮スパイク数を10分間隔で計測した。
Analysis of gastric motility is performed using methods such as TAKEUCH1 (Take
uchi et al., Dig, Dis, Se4. , 31
.. 1114-1122, (19g+1)), the contraction frequency per 10 minutes was measured. That is, 20CmH2
The number of contraction spikes showing 0 or more was measured at 10 minute intervals.

なお、被験液投与前の収縮数を100%とし、投与後の
頻度変化を算出した。
Note that the number of contractions before administration of the test solution was taken as 100%, and the change in frequency after administration was calculated.

結果を下記の表に示す。The results are shown in the table below.

*;  P<0. 05 表から明らかなように、従来の内服製剤を想定した薬物
の直接胃内投与では一過性の胃運動抑制傾向が認められ
るのに対し、チュアブル錠を想定した口腔内及び胃内の
同時投与では投与後直ちに胃運動が互違し、さらに持続
的に阿運動亢進作用を示した。このことより、チュアブ
ル錠による投与方法が従来の内服製剤による投与方法よ
りも胃運動亢進作用の強度、発現速度(速効性)、持続
性において優れ、健胃薬としての有用性が極めて高いこ
とがボされた。
*; P<0. 05 As is clear from the table, there is a tendency to transiently suppress gastric motility when the drug is administered directly into the stomach in the form of a conventional oral preparation, whereas simultaneous intraoral and intragastric administration in the form of a chewable tablet Immediately after administration, gastric motility was altered, and furthermore, the drug showed a sustained action to increase motility. From this, the main point is that the administration method using chewable tablets is superior to the administration method using conventional oral preparations in terms of the strength, speed of onset (fast-acting), and sustainability of the gastric motility-promoting effect, and is extremely useful as a stomachic drug. It was done.

[実施例] 次に、実施例を挙げて本発明を具体的に説明するが、本
発明は何らこれらに限定されるものではない。
[Example] Next, the present invention will be specifically described with reference to Examples, but the present invention is not limited to these in any way.

また、実施例中の錠剤の硬度は/ユロイニゲル硬度Mt
 (2E ’Jl: Dr、R,Sehlenuige
r & Co、)により測定した。崩壊時間は日本薬局
方一般試験法崩壊試験法(2)錠剤の項に準じて准I定
した。
In addition, the hardness of the tablets in the examples is /Uroinigel hardness Mt
(2E 'Jl: Dr. R. Sehlenuige
r & Co,). The disintegration time was determined in accordance with the Japanese Pharmacopoeia General Test Method Disintegration Test Method (2) Tablet section.

実施例1 ウィキョウ油0.25%、ケイヒ油03%、チョウジ油
0.】%及びホップ乾燥エキス0.5%を配合した還元
麦芽糖水飴の均一混合物に合成硅酸アルミニウム2%及
びステアリン酸マグネンウム1%を添加して、15mm
径の杵を用いて1錠1000mgのチュアブル錠を製し
た。
Example 1 Fennel oil 0.25%, cinnamon bark oil 03%, clove oil 0. ] 2% synthetic aluminum silicate and 1% magnesium stearate were added to a homogeneous mixture of reduced maltose starch syrup containing 0.5% hop dry extract and 0.5% hop dry extract to make 15 mm
Chewable tablets each weighing 1000 mg were prepared using a punch with a diameter of 100 mL.

このチュアブル錠の硬度はlO〜13 K g / c
m2であり、崩壊時間は10−15分であった。
The hardness of this chewable tablet is lO~13K g/c
m2 and disintegration time was 10-15 minutes.

実施例2 ウイキタウ油0.5%、ケイヒ油0.6%、チ、ウジ油
0,2%及び1−メントール5九ヲ配合したマンニトー
ルにマクロゴール6000 10%、合成硅酸アルミニ
ウム3%及びステアリン酸マグネ/ウム1%を配合して
10mm径の杵で1錠500mgのチェアブル錠を製し
た。
Example 2 Mannitol mixed with 0.5% Wikitau oil, 0.6% cinnamon oil, 0.2% Chi, Maggot oil, and 59 1-menthol, 10% Macrogol 6000, 3% synthetic aluminum silicate, and stearin. A 500 mg chewable tablet was prepared by blending 1% magnesium/um acid with a 10 mm diameter punch.

このチュアブル錠の硬度は、8〜I OK g / c
m2、崩壊時間は12〜16分であった。
The hardness of this chewable tablet is 8~I OK g/c
m2, disintegration time was 12-16 minutes.

実施例3 ンウジュン乾燥エキス15g、7mつ牛1つ乾燥エキス
10g、乳糖250 g、  マンニトール680g及
びヒドロ牛/プロピルセルロースlogの均一混合物に
精製水170m1を加え造粒する。
Example 3 170 ml of purified water was added to a homogeneous mixture of 15 g of Nunjun dry extract, 10 g of 7m cow dry extract, 250 g of lactose, 680 g of mannitol, and log of hydrobovine/propyl cellulose and granulated.

乾燥した後、ウイキBつ14g1 ケイヒ2Qg及びス
テアリン酸マグネ/ウムIgを配合して、15mm径の
杵で1錠1000mgのチコアブル錠を製した。
After drying, 14 g of Wiki B, 2 Q g of cinnamon and Ig of magnesium/ium stearate were blended, and each 1000 mg Chicoable tablet was made using a 15 mm diameter punch.

このチニアブル錠の硬度は、9〜12 K g / c
tn”、  崩壊時間は8〜13分であった。
The hardness of this chiniable tablet is 9-12 Kg/c
tn'', the disintegration time was 8-13 minutes.

実施例4 オウレン乾燥エキス18 g、  コウボク乾燥エキス
170 g、  シーウキ冒つ乾燥エキス75g1 ニ
ンジン乾燥エキス35g、白糖1200g、乳糖zoo
g、及びデンプン102gを均一に混合し、精製水40
0m1を加え造粒し乾燥する。この顆粒2000gに、
ケイヒ油5g及びチ四つジ油2gを硅酸アルミニウム2
0gで粉末化した混合床10g及びステアリン酸マグネ
ンウム2gを加え均一に混合した後、13mm径の杵で
1錠900mgのチュアブル錠を製した。
Example 4 18 g of dried extract of Orensis oleracea, 170 g of dried extract of Kobokko, 75 g of dried extract of C. oleracea, 35 g of dried carrot extract, 1200 g of white sugar, lactose zoo
and 102 g of starch, and 40 g of purified water.
Add 0ml, granulate and dry. To 2000g of this granules,
5g of cinnamon bark oil and 2g of cinnamon oil and 2g of aluminum silicate
After adding 10 g of the mixed bed powdered at 0 g and 2 g of magnesium stearate and mixing uniformly, chewable tablets each weighing 900 mg were prepared using a 13 mm diameter pestle.

このチェアブル錠の硬度はlO〜13 K g / c
m2、崩壊時間は12〜15分であった。
The hardness of this chairable tablet is lO~13K g/c
m2, disintegration time was 12-15 minutes.

[発明の効果] 本発明の生薬を配合するチュアブル錠は胃粘膜への直接
作用はもとより、味覚・嗅覚を刺激して唾液・胃液の分
泌と消化管の運動を強力、速効的かつ持続的に高める作
用を併せ持ち、健胃薬として極めて有用なものである。
[Effects of the invention] The chewable tablet containing the herbal medicine of the present invention not only has a direct effect on the gastric mucosa, but also stimulates the sense of taste and smell and strongly, rapidly, and sustainably stimulates saliva and gastric juice secretion and gastrointestinal motility. It also has a stimulating effect, making it extremely useful as a stomachic medicine.

Claims (1)

【特許請求の範囲】[Claims] 生薬を配合することを特徴とするチュアブル錠Chewable tablets characterized by containing crude drugs
JP2205109A 1990-08-03 1990-08-03 Herbal medicine chewable tablets Expired - Lifetime JPH0739350B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2205109A JPH0739350B2 (en) 1990-08-03 1990-08-03 Herbal medicine chewable tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2205109A JPH0739350B2 (en) 1990-08-03 1990-08-03 Herbal medicine chewable tablets

Publications (2)

Publication Number Publication Date
JPH0491029A true JPH0491029A (en) 1992-03-24
JPH0739350B2 JPH0739350B2 (en) 1995-05-01

Family

ID=16501573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2205109A Expired - Lifetime JPH0739350B2 (en) 1990-08-03 1990-08-03 Herbal medicine chewable tablets

Country Status (1)

Country Link
JP (1) JPH0739350B2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733394A1 (en) * 1995-04-28 1996-10-31 Braure Jacques Health promoting dietary prod. for dogs and cats
WO1997012606A1 (en) * 1995-10-03 1997-04-10 Chugai Seiyaku Kabushiki Kaisha Chewable tablet
WO2000047233A1 (en) * 1999-02-15 2000-08-17 Sumitomo Pharmaceuticals Co., Ltd. Tablets quickly disintegrated in the oral cavity
WO2002074319A1 (en) * 2001-03-15 2002-09-26 M.B. Pharmos A/S Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases
KR100844378B1 (en) * 2006-12-07 2008-07-07 한국 한의학 연구원 Pharmaceutical composition for treating and preventing gastrointestinal diseases comprising herb extracts
JP2013075858A (en) * 2011-09-30 2013-04-25 Kobayashi Pharmaceutical Co Ltd Composition for oral cavity
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
CN105747212A (en) * 2016-02-25 2016-07-13 中国科学院西北高原生物研究所 Cynomorium songaricum product for protecting gastric mucosa and preparation technology thereof
CN107441470A (en) * 2017-08-04 2017-12-08 顾海婷 A kind of Chinese medicine for treating stomach cold

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203010A (en) * 1981-05-29 1982-12-13 Nabisco Brands Inc Compressed mastication tablet and manufacture
JPS6169729A (en) * 1984-09-14 1986-04-10 Kyodo Kenko Shizen Shokuhin Kk Production of powdered essence of nonbitter light

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567819A (en) 1969-01-30 1971-03-02 Hoffmann La Roche Cold tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203010A (en) * 1981-05-29 1982-12-13 Nabisco Brands Inc Compressed mastication tablet and manufacture
JPS6169729A (en) * 1984-09-14 1986-04-10 Kyodo Kenko Shizen Shokuhin Kk Production of powdered essence of nonbitter light

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733394A1 (en) * 1995-04-28 1996-10-31 Braure Jacques Health promoting dietary prod. for dogs and cats
WO1997012606A1 (en) * 1995-10-03 1997-04-10 Chugai Seiyaku Kabushiki Kaisha Chewable tablet
AU705102B2 (en) * 1995-10-03 1999-05-13 Chugai Seiyaku Kabushiki Kaisha Chewable tablets
US6146661A (en) * 1995-10-03 2000-11-14 Chugai Seiyaku Kabushiki Kaisha Chewable tablet
WO2000047233A1 (en) * 1999-02-15 2000-08-17 Sumitomo Pharmaceuticals Co., Ltd. Tablets quickly disintegrated in the oral cavity
WO2002074319A1 (en) * 2001-03-15 2002-09-26 M.B. Pharmos A/S Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
KR100844378B1 (en) * 2006-12-07 2008-07-07 한국 한의학 연구원 Pharmaceutical composition for treating and preventing gastrointestinal diseases comprising herb extracts
JP2013075858A (en) * 2011-09-30 2013-04-25 Kobayashi Pharmaceutical Co Ltd Composition for oral cavity
CN105747212A (en) * 2016-02-25 2016-07-13 中国科学院西北高原生物研究所 Cynomorium songaricum product for protecting gastric mucosa and preparation technology thereof
CN107441470A (en) * 2017-08-04 2017-12-08 顾海婷 A kind of Chinese medicine for treating stomach cold

Also Published As

Publication number Publication date
JPH0739350B2 (en) 1995-05-01

Similar Documents

Publication Publication Date Title
Aly et al. Licorice: a possible anti-inflammatory and anti-ulcer drug
EP0487520B1 (en) Compressed powder medicaments
US20110014132A1 (en) Solid effervescent mixture for the oral absorption
KR0145739B1 (en) Effervescent tablet
WO1999018936A1 (en) Quickly soluble solid preparations
KR101203186B1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
US6455077B2 (en) Herbal composition and method of manufacturing such composition for the management of gynecological disorders
CN101277721B (en) Orally disintegrating tablet
CN1561214A (en) New formulations and use thereof
JPH04234324A (en) Digestable sucralphate tablet
JPH0491029A (en) Galenical drug blended chewable tablet
RU2126249C1 (en) Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions
JPH11199517A (en) Intraoral fast disintegrable tablet
KR101175120B1 (en) Nateglinide-containing preparation
CN101152156A (en) Domperidone orally disintegrating tablets and method for preparing the same
CN101401796A (en) Pramipexole orally disintegrating tablets and preparation method thereof
JPH0426618A (en) Troche
TWI343818B (en)
US6274172B1 (en) Therapeutic effervescent compositions
JPH0656677A (en) Antacid composition
CN101269055B (en) Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same
CN107343926B (en) Traditional Chinese medicine composition for treating recurrent oral ulcer
KR101254511B1 (en) Gastrointestinal drug composition
JP4786166B2 (en) Antacid composition
JP2005272401A (en) Chewable tablet